{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:25:19Z","timestamp":1791473119922,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ymthe.2023.03.036","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T21:25:54Z","timestamp":1680557154000},"page":"1418-1436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia"],"prefix":"10.1016","volume":"31","author":[{"given":"Boya","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thach Tuan","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Yew Meng","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pirisinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Migara Kavishka","family":"Jayasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin Chanh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ng","family":"Shyh-Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-1566","authenticated-orcid":false,"given":"Minh T.N.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.03.036_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fonc.2020.00298","article-title":"Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options","volume":"10","author":"Marceca","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.036_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-020-00288-6","article-title":"Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia","volume":"10","author":"Rausch","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ymthe.2023.03.036_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.036_bib4","first-page":"1","article-title":"Cancer cachexia: medical management","volume":"18","author":"Mantovani","year":"2010","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ymthe.2023.03.036_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","article-title":"Cancer cachexia\u2014pathophysiology and management","volume":"48","author":"Suzuki","year":"2013","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.ymthe.2023.03.036_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijcard.2014.10.026","article-title":"Treatment of cachexia: an overview of recent developments","volume":"184","author":"von Haehling","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymthe.2023.03.036_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jcsm.12402","article-title":"Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review","volume":"10","author":"Anker","year":"2019","journal-title":"J.\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ymthe.2023.03.036_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13395-016-0098-2","article-title":"ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments","volume":"6","author":"Hatakeyama","year":"2016","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2023.03.036_bib9","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ijc.29930","article-title":"Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and \u03b2-2 agonist","volume":"138","author":"Toledo","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.03.036_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2023.03.036_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.03.036_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148372","article-title":"Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction","volume":"131","author":"Lee","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.03.036_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.gt.3303016","article-title":"Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice","volume":"15","author":"Liu","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.03.036_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ymthe.2023.03.036_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2023.03.036_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nm.4093","article-title":"Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia","volume":"22","author":"Fukawa","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.036_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1198973","article-title":"Adipose triglyceride lipase contributes to cancer-associated cachexia","volume":"333","author":"Das","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.03.036_bib18","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1161\/01.RES.0000129255.19569.8f","article-title":"Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation","volume":"94","author":"Dyck","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2023.03.036_bib19","first-page":"1105","article-title":"Decrease in malonyl-CoA and its background metabolic alterations in murine model of cancer cachexia","volume":"21","author":"Celik","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ymthe.2023.03.036_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2052-8426-2-5","article-title":"Harnessing RNAi nanomedicine for precision therapy","volume":"2","author":"Peer","year":"2014","journal-title":"Mol. Cell. Ther."},{"key":"10.1016\/j.ymthe.2023.03.036_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.addr.2007.06.003","article-title":"Biodegradable nanoparticles for cytosolic delivery of therapeutics","volume":"59","author":"Vasir","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2023.03.036_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","article-title":"In\u00a0vivo toxicity of cationic micelles and liposomes","volume":"11","author":"Knudsen","year":"2015","journal-title":"Nanomedicine."},{"key":"10.1016\/j.ymthe.2023.03.036_bib23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.285.5433.1569","article-title":"In\u00a0vivo protein transduction: delivery of a biologically active protein into the mouse","volume":"285","author":"Schwarze","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.03.036_bib24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI87316","article-title":"Extracellular vesicles: masters of intercellular communication and potential clinical interventions","volume":"126","author":"Pitt","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.03.036_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: Biology and emerging therapeutic opportunities","volume":"12","author":"EL Andaloussi","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2023.03.036_bib26","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","article-title":"Efficient RNA drug delivery using red blood cell extracellular vesicles","volume":"9","author":"Usman","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.03.036_bib27","article-title":"Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery","volume":"10","author":"Pham","year":"2021","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2023.03.036_bib28","article-title":"Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy","volume":"11","author":"Peng","year":"2022","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2023.03.036_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2023.03.036_bib30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/SPC.0000000000000013","article-title":"Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders","volume":"7","author":"Smith","year":"2013","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.ymthe.2023.03.036_bib31","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1038\/s41598-018-24676-6","article-title":"The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations","volume":"8","author":"O\u2019Connor","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.03.036_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2003782","article-title":"Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of \u03b2-oxidation","volume":"16","author":"Yao","year":"2018","journal-title":"Plos Biol."},{"key":"10.1016\/j.ymthe.2023.03.036_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009176","article-title":"Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice","volume":"5","author":"Morine","year":"2010","journal-title":"PloS one"},{"key":"10.1016\/j.ymthe.2023.03.036_bib34","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1038\/mtna.2016.55","article-title":"Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth","volume":"5","author":"Khan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2023.03.036_bib35","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.03.036_bib36","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1002\/jex2.59","article-title":"Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina","volume":"1","author":"Driedonks","year":"2022","journal-title":"J.\u00a0Extracell. Biol."},{"key":"10.1016\/j.ymthe.2023.03.036_bib37","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1039\/C8NR08720B","article-title":"Extracellular vesicles induce minimal hepatotoxicity and immunogenicity","volume":"11","author":"Saleh","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.ymthe.2023.03.036_bib38","article-title":"Measuring the strength of mice","volume":"76","author":"Deacon","year":"2013","journal-title":"J.\u00a0Vis. Exp."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162300196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162300196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:08:32Z","timestamp":1761502112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162300196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S152500162300196X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.036","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}